Randomized, Double-blind (for Clazosentan), Placebo- and Moxifloxacincontrolled, 3-way Cross-over Phase 1 Study to Assess the Effect of Two Intravenous Doses of Clazosentan on the QTc Interval Duration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2018
At a glance
- Drugs Clazosentan (Primary)
- Indications Cerebral vasospasm
- Focus Adverse reactions
- Sponsors Idorsia Pharmaceuticals
- 19 Nov 2018 Status changed from recruiting to completed.
- 22 Oct 2018 Status changed from not yet recruiting to recruiting.
- 12 Sep 2018 New trial record